Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1983 Oct;20(5):330–333. doi: 10.1136/jmg.20.5.330

The association of the slow acetylator phenotype with bladder cancer.

D A Evans, L C Eze, E J Whibley
PMCID: PMC1049143  PMID: 6644762

Abstract

There is an association between exposure to aromatic amines and the development of bladder cancer. Aromatic amines such as are known to occur in tobacco smoke are polymorphically acetylated. One hundred bladder cancer patients have been acetylator phenotyped. Only three of them were non-smokers at the time of diagnosis. This new series, together with four previous series (each with its own control), have been statistically analysed together. The results show a significant association between the slow acetylator phenotype and bladder cancer. The slow acetylator phenotype is associated about 39% more with bladder cancer than is the rapid acetylator phenotype. This association can be interpreted in one of two ways: (1) rapid acetylators may be protected against developing bladder cancer because they are better able to render amines non-carcinogenic by acetylation, or (2) slow acetylators have greater survival with bladder cancer than rapid acetylators. Further evidence will be required to differentiate between these alternatives.

Full text

PDF
330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cartwright R. A., Glashan R. W., Rogers H. J., Ahmad R. A., Barham-Hall D., Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982 Oct 16;2(8303):842–845. doi: 10.1016/s0140-6736(82)90810-8. [DOI] [PubMed] [Google Scholar]
  2. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
  4. Ellard G. A., Gammon P. T., Titinen H. Determination of the acetylator phenotype using matrix isoniazid. Tubercle. 1975 Sep;56(3):203–209. doi: 10.1016/0041-3879(75)90053-7. [DOI] [PubMed] [Google Scholar]
  5. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans D. A., Bullen M. F., Houston J., Hopkins C. A., Vetters J. M. Antinuclear factor in rapid and slow acetylator patients treated with isoniazid. J Med Genet. 1972 Mar;9(1):53–56. doi: 10.1136/jmg.9.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eze L. C., Evans D. A. The use of the autoanalyzer to determine the acetylator phenotype. J Med Genet. 1972 Mar;9(1):57–59. doi: 10.1136/jmg.9.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. GOW J. G., EVANS D. A. A STUDY OF THE INFLUENCE OF THE ISONIAZID INACTIVATOR PHENOTYPE ON REVERSION IN GENITO-URINARY TUBERCULOSIS. Tubercle. 1964 Jun;45:136–143. doi: 10.1016/s0041-3879(64)80071-4. [DOI] [PubMed] [Google Scholar]
  9. Glowinski I. B., Radtke H. E., Weber W. W. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol Pharmacol. 1978 Sep;14(5):940–949. [PubMed] [Google Scholar]
  10. Glowinski I. B., Weber W. W., Fysh J. M., Vaught J. B., King C. M. Evidence that arylhydroxamic acid N,O-acyltransferase and the genetically polymorphic N-acetyltransferase are properties of the same enzyme in rabbit liver. J Biol Chem. 1980 Aug 25;255(16):7883–7890. [PubMed] [Google Scholar]
  11. Glowinski I. B., Weber W. W. Genetic regulation of aromatic amine N-acetylation in inbred mice. J Biol Chem. 1982 Feb 10;257(3):1424–1430. [PubMed] [Google Scholar]
  12. HALDANE J. B. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet. 1956 May;20(4):309–311. doi: 10.1111/j.1469-1809.1955.tb01285.x. [DOI] [PubMed] [Google Scholar]
  13. Karim A. K., Elfellah M. S., Evans D. A. Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J Med Genet. 1981 Oct;18(5):325–330. doi: 10.1136/jmg.18.5.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karim A. K., Evans D. A. Polymorphic acetylation of nitrazepam. J Med Genet. 1976 Feb;13(1):17–19. doi: 10.1136/jmg.13.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lower G. M., Jr, Nilsson T., Nelson C. E., Wolf H., Gamsky T. E., Bryan G. T. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect. 1979 Apr;29:71–79. doi: 10.1289/ehp.792971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schröder H., Evans D. A. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972 Apr;13(4):278–284. doi: 10.1136/gut.13.4.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schröder H., Evans D. A. The polymorphic acetylation of sulphapyridine in man. J Med Genet. 1972 Jun;9(2):168–171. doi: 10.1136/jmg.9.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schröder H., Lewkonia R. M., Price Evans D. A. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital. Clin Pharmacol Ther. 1973 Sep-Oct;14(5):802–809. doi: 10.1002/cpt1973145802. [DOI] [PubMed] [Google Scholar]
  19. Víznerová A., Slavíková Z., Ellard G. A. The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tubercle. 1973 Mar;54(1):67–71. doi: 10.1016/0041-3879(73)90016-0. [DOI] [PubMed] [Google Scholar]
  20. WOOLF B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955 Jun;19(4):251–253. doi: 10.1111/j.1469-1809.1955.tb01348.x. [DOI] [PubMed] [Google Scholar]
  21. Weber W. W., Brenner W. A filter paper method for determining isoniazid acetylator phenotype. Am J Hum Genet. 1974 Jul;26(4):467–473. [PMC free article] [PubMed] [Google Scholar]
  22. White T. A., Evans D. A. The actylation of sulamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):80–88. doi: 10.1002/cpt19689180. [DOI] [PubMed] [Google Scholar]
  23. Woodhouse K. W., Adams P. C., Clothier A., Mucklow J. C., Rawlins M. D. N-acetylation phenotype in bladder cancer. Hum Toxicol. 1982 Oct;1(4):443–445. doi: 10.1177/096032718200100411. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES